Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Current Assets (2016 - 2025)

Historic Current Assets for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $66.5 million.

  • Protalix BioTherapeutics' Current Assets rose 3897.14% to $66.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.5 million, marking a year-over-year increase of 3897.14%. This contributed to the annual value of $60.1 million for FY2024, which is 1409.08% down from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Current Assets stood at $66.5 million, which was up 3897.14% from $65.5 million recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Current Assets peaked at $95.9 million during Q2 2021, and registered a low of $44.9 million during Q4 2022.
  • Over the past 5 years, Protalix BioTherapeutics' median Current Assets value was $65.5 million (recorded in 2025), while the average stood at $65.3 million.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Current Assets soared by 7694.71% in 2021, and later plummeted by 4818.76% in 2022.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Current Assets stood at $61.7 million in 2021, then fell by 27.22% to $44.9 million in 2022, then skyrocketed by 55.82% to $69.9 million in 2023, then dropped by 14.09% to $60.1 million in 2024, then grew by 10.69% to $66.5 million in 2025.
  • Its Current Assets was $66.5 million in Q3 2025, compared to $65.5 million in Q2 2025 and $60.5 million in Q1 2025.